Champions Oncology to Announce Fourth Quarter Financial Results on Thursday, July 21, 2022

HACKENSACK, NJ / ACCESSWIRE / July 14, 2022 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the fourth quarter ended April 30, 2022, on Thursday, July 21, 2022, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 908668. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 46134, or by accessing the investors section of the company's website within 72 hours.

About Champions Oncology, Inc.

Champions Oncology is a technology-driven research organization that develops innovative therapeutics against cancer targets, offers groundbreaking research software as a service, and provides end-to-end R&D services to biopharma organizations. Champions Oncology is actively engaged in the transformation of drug discovery through a novel approach of pharmaco-pheno-multiomic integration. For more information, please visit www.ChampionsOncology.com.

SOURCE: Champions Oncology, Inc.



View source version on accesswire.com:
https://www.accesswire.com/708456/Champions-Oncology-to-Announce-Fourth-Quarter-Financial-Results-on-Thursday-July-21-2022

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  239.16
+4.82 (2.06%)
AAPL  248.04
-0.31 (-0.12%)
AMD  259.68
+5.95 (2.35%)
BAC  51.72
-0.73 (-1.39%)
GOOG  328.43
-2.41 (-0.73%)
META  658.76
+11.13 (1.72%)
MSFT  465.95
+14.81 (3.28%)
NVDA  187.67
+2.83 (1.53%)
ORCL  177.16
-1.02 (-0.57%)
TSLA  449.06
-0.30 (-0.07%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.